The continuous bioprocessing market has witnessed significant growth in the recent years owing to increasing demand for advanced bioprocessing technologies in the pharmaceutical industry. Continuous bioprocessing involves designing, developing and utilizing bioprocess equipment and methodologies that can continuously transform raw materials into desired products. It helps to achieve optimal productivity levels by eliminating equipment cleaning, start-up and shutdown times. Some key advantages of continuous bioprocessing include improved process economics, better asset utilization, reduced energy consumption and enhanced product quality. The growing need for high-quality biologics at reduced costs is a major factor driving the adoption of continuous bioprocessing approaches.
The Continuous bioprocessing market is estimated to be valued at US$ 395 Mn in 2024 and is expected to exhibit a CAGR of 8.4% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the continuous bioprocessing market are AGC Biologics, Biogen, Bristol-Myers Squibb, Sanofi Genzyme, FUJIFILM Diosynth Biotechnologies and Others. AGC Biologics is one of the leading contract development and manufacturing organizations for biopharmaceuticals with significant presence in continuous bioprocessing. Biogen is a pioneer in developing continuous manufacturing technologies for monoclonal antibodies.
The key opportunities in the continuous bioprocessing market include developing integrated continuous platforms for multi-step bio manufacturing and single-use technologies. Integrated systems allow for developing complex biologics through linked, continuous unit operations without interruptions. Single-use technologies help eliminate cross-contamination risks and reduce validation requirements.
Globally, North America is expected to continue dominating the continuous bioprocessing market during the forecast period. However, Asia Pacific is likely to witness the highest growth owing to increasing investments by leading pharmaceutical companies in developing continuous bioprocessing capabilities in China and India. Europe is also expected exhibit steady growth due to ongoing support for continuous processing from regulatory agencies in the region.
Market Drivers
Demand for cost-effective biopharma manufacturing: Continuous bioprocessing significantly reduces manufacturing costs through optimal asset utilization and enhanced productivity. This is a major driver as biopharmaceutical manufacturers seek affordable production methods.
Regulatory push for advanced technologies: Agencies like EMA and FDA are encouraging development and adoption of novel continuous manufacturing technologies through various programs. For example, FDA's Process Analytical Technology (PAT) initiative promotes process analyzers for continuous processes. This is fueling investments in continuous bioprocessing R&D.
Market Restrains
High capital investment: Setting up continuous bioprocessing facilities requires huge capital expenditure, which can be challenging for small companies. Returns may take long time due to high developmental risks. This acts as a major restrain.
Lack of skilled workforce: Continuous manufacturing involves intricate process engineering concepts. There is a significant capability gap in terms of workforce with expert knowledge of continuous bioprocessing technologies. This hampers faster adoption of continuous approaches.
Segment Analysis
The continuous bioprocessing market is segmented by product, application and end user. The product segment is further segmented into bioreactors, Filtration systems, blending systems and storage systems. Among these, the bioreactors segment accounted for the largest market share in 2020 due to increasing preference for single use bioreactors by biopharmaceutical manufacturers. Single-use bioreactors offer advantages such as lower capital expenditure, reduced validation requirements, and less technical challenges compared to traditional stainless steel bioreactors. By application, monoclonal antibodies dominated the market owing to increasing demand for monoclonal antibody therapeutics for treating various chronic diseases like cancer. The end user segment is classified into biopharmaceutical companies, CROs, academia and research institutes and others. Biopharmaceutical companies are the dominating end user segment due to preference for continuous bioprocessing systems to meet increasing demand while ensuring quality and production efficiency.
Global Analysis
The North American region accounted for the largest share of the Continuous bioprocessing market in 2020 due to presence of leading biopharmaceutical companies and availability of funding for research & development in continuous bioprocessing in the region. However, Asia Pacific region is expected to witness highest growth during the forecast period owing to increasing government support for biologics manufacturing, improving healthcare infrastructure and expanding biopharmaceutical industry in emerging economies like China and India. Key players are also focusing on establishing manufacturing facilities in Asia to leverage low-cost production and cater to rising local demand.
Get more insights on this topic: https://www.dailyprbulletin.com/the-continuous-bioprocessing-market-is-primed-for-growth-by-automation-trends/
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
What Are The Key Data Covered In This Continuous Bioprocessing Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Continuous Bioprocessing's growth between 2024 and 2031.
:- Accurate calculation of the size of the Continuous Bioprocessing and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Continuous Bioprocessing Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Continuous Bioprocessing vendors
FAQ’s
Q.1 What are the main factors influencing the Continuous Bioprocessing?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Continuous Bioprocessing companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Continuous Bioprocessing’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it